Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Window of opportunity for daclizumab

Nature Medicine volume 17, pages 545–547 (2011)Cite this article

Subjects

Interleukin-2 receptor-α (IL-2Rα) on antigen-presenting dendritic cells (DCs) is now shown to trans-present IL-2 to T cells during the earliest stages of T cell activation (604–609). The resulting T cell proliferation is blocked by daclizumab, an IL-2Rα–specific antibody used to treat multiple sclerosis and prevent transplant rejection, highlighting the importance of understanding individual variability in immune responses to daclizumab treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: DCs provide IL-2 to T cells via trans-presentation during the earliest steps of T cell activation.

Marina Corral

References

  1. Mottershead, M. & Neuberger, J. Expert Opin. Biol. Ther. 7, 1583–1596 (2007).

    Article  CAS  Google Scholar 

  2. Wang, H.M. & Smith, K.A. J. Exp. Med. 166, 1055–1069 (1987).

    Article  CAS  Google Scholar 

  3. Wuest, S.C. et al. Nat. Med. 17, 604–609 (2011).

    Article  CAS  Google Scholar 

  4. Bielekova, B. et al. Proc. Natl. Acad. Sci. USA 103, 5941–5946 (2006).

    Article  CAS  Google Scholar 

  5. Martin, J.F., Perry, J.S., Jakhete, N.R., Wang, X. & Bielekova, B. J. Immunol. 185, 1311–1320 (2010).

    Article  CAS  Google Scholar 

  6. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. J. Exp. Med. 201, 723–735 (2005).

    Article  CAS  Google Scholar 

  7. Velten, F.W., Rambow, F., Metharom, P. & Goerdt, S. Mol. Immunol. 44, 1544–1550 (2007).

    Article  CAS  Google Scholar 

  8. Dubois, S., Mariner, J., Waldmann, T.A. & Tagaya, Y. Immunity 17, 537–547 (2002).

    Article  CAS  Google Scholar 

  9. Granucci, F. et al. Nat. Immunol. 2, 882–888 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kimberly S. Schluns is in the Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.,

    Kimberly S Schluns

Authors
  1. Kimberly S Schluns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberly S Schluns.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schluns, K. Window of opportunity for daclizumab. Nat Med 17, 545–547 (2011). https://doi.org/10.1038/nm0511-545

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0511-545

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing